

Theresa Hydes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6113154/theresa-hydes-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32
papers

531
citations

12
h-index

22
g-index

40
ext. papers

822
ext. citations

5.7
avg, IF

4.09
L-index

#	Paper	IF	Citations
32	The Impact of the COVID-19 Pandemic on Mobility Trends and the Associated Rise in Population-Level Physical Inactivity: Insights From International Mobile Phone and National Survey Data.. <i>Frontiers in Sports and Active Living</i> , 2022 , 4, 773742	2.3	1
31	Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care.. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
30	A spotlight on natural killer cells in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021 , 74, 254-255	13.4	1
29	Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data. <i>BMJ Open</i> , 2021 , 11, e044952	3	1
28	The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?. <i>Frontiers in Nutrition</i> , 2021 , 8, 640557	6.2	7
27	Validation of the liver traffic light test as a predictive model for survival and development of liver-related events. <i>JGH Open</i> , 2021 , 5, 549-557	1.8	1
26	Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. <i>Diabetic Medicine</i> , 2020 , 37, 1793-1806	3.5	5
25	Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 383-400	6.9	17
24	Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. <i>BMJ Open</i> , 2020 , 10, e040970	3	3
23	A comparison of gender-linked population cancer risks between alcohol and tobacco: how many cigarettes are there in a bottle of wine?. <i>BMC Public Health</i> , 2019 , 19, 316	4.1	74
22	Constitutive Activation of Natural Killer Cells in Primary Biliary Cholangitis. <i>Frontiers in Immunology</i> , 2019 , 10, 2633	8.4	7
21	Treating alcohol-related liver disease from a public health perspective. <i>Journal of Hepatology</i> , 2019 , 70, 223-236	13.4	22
20	National Early Warning Score Accurately Discriminates the Risk of Serious Adverse Events in Patients With Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1657-1666.e10	6.9	6
19	IL-12 and IL-15 induce the expression of CXCR6 and CD49a on peripheral natural killer cells. <i>Immunity, Inflammation and Disease</i> , 2018 , 6, 34-46	2.4	34
18	STAT4-associated natural killer cell tolerance following liver transplantation. <i>Gut</i> , 2017 , 66, 352-361	19.2	17
17	HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. <i>Journal of Hepatology</i> , 2017 , 67, 462-470	13.4	15
16	Innate and adaptive genetic pathways in HCV infection. <i>Tissue Antigens</i> , 2015 , 85, 231-40		11

15	Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S45	4.0	16
14	Alcoholic liver disease - the extent of the problem and what you can do about it. <i>Clinical Medicine</i> , 2015 , 15, 179-85	1.9	18
13	The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways. <i>Tissue Antigens</i> , 2015 , 86, 267-75		9
12	Nitrofurantoin immune-mediated drug-induced liver injury: a serious complication of a commonly prescribed medication. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	6
11	An evaluation of patient attitudes to colonoscopy and the importance of endoscopist interaction and the endoscopy environment to satisfaction and value. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 366-73	2.4	28
10	Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. <i>Hepatology</i> , 2013 , 58, 881-9	11.2	15
9	District general hospital networks can provide safe and effective hepatitis C treatment: results of a 5-year audit. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 942-7	2.2	1
8	PMO-173 District general hospital networks can provide safe and effective hepatitis C treatment: results of a 4-year audit. <i>Gut</i> , 2012 , 61, A144.1-A144	19.2	1
7	Lean thinking transformation of the unседated upper gastrointestinal endoscopy pathway improves efficiency and is associated with high levels of patient satisfaction. <i>BMJ Quality and Safety</i> , 2012 , 21, 63-9	5.4	27
6	PWE-289 Critical illness early warning scores retain accuracy in patients with liver disease: an analysis of 182 000 inpatient observation sets. <i>Gut</i> , 2012 , 61, A415.2-A416	19.2	
5	Subacute liver failure secondary to amyloid light-chain amyloidosis. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 205-8	0.7	2
4	Innate immunity: a new chapter for hepatitis C. <i>Annals of Gastroenterology</i> , 2012 , 25, 232-240	2.2	
3	Cirrhosis and a metallic foreign body in the stomach. <i>Liver International</i> , 2011 , 31, 1541	7.9	
2	A survey of patients' attitudes to upper gastrointestinal endoscopy identifies the value of endoscopist-patient interactive factors. <i>Frontline Gastroenterology</i> , 2011 , 2, 242-248	2.6	5
1	Process mapping the patient journey: an introduction. <i>BMJ, The</i> , 2010 , 341, c4078	5.9	165